In a nutshell This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the pandemic. Some...
Read More
In a nutshell This study is aimed to evaluate the risk of infection for patients who are treated with immune checkpoint inhibitors (ICI) for solid tumors. The study concluded that in frail patients, ICI therapy alone is safer compared to chemotherapy (CT). Some background Immunotherapy is a type of cancer treatment that makes use of the immune...
Read More
In a nutshell This study is aimed to evaluate the risk of infection for patients who are treated with immune checkpoint inhibitors (ICI) for solid tumors. The study concluded that in frail patients, ICI therapy alone is safer compared to chemotherapy (CT). Some background Immunotherapy is a type of cancer treatment that makes use of the...
Read More
In a nutshell This study compared the effectiveness and safety of S-1 (tegafur/gimeracil/oteracil) and oxaliplatin (Eloxatin) combined with bevacizumab (Avastin) or with cetuximab (Erbitux) in patients with previously untreated advanced colorectal cancer with wild-type KRAS. This study concluded that the safety and effectiveness of...
Read More
In a nutshell This study investigated the effectiveness and safety of preventative antibiotic treatment with clarithromycin (Biaxin) to prevent skin-related side effects associated with panitumumab (Vectibix) treatment for patients with metastatic colorectal cancer (mCRC). The data showed that clarithromycin administered daily along with a simple...
Read More
In a nutshell This study evaluated the association between patient-reported outcomes (PROs) and survival outcomes in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (BC) treated with abemaciclib (Verzenio). The data showed that the PROs could be a predictor of survival benefits in these patients. Some...
Read More
In a nutshell This study was carried out to see whether a reduction in inflammatory marker C-reactive protein (CRP) following treatment with atezolizumab (Tecentriq) is associated with an improved survival in patients with non-small cell lung cancer (NSCLC). The authors found that a lower CRP following treatment was associated with improved...
Read More
In a nutshell This article analyzed the safety and effectiveness of an immunotherapy (IT) and radiotherapy (RT) combination to treat patients with non-small cell lung cancer (NSCLC). The authors found that combination therapy using an immunotherapy drug such as PD-1/PD-L1 inhibitors and RT may improve the outcomes of these patients. Some background...
Read More
In a nutshell This study looked at the outcomes of durvalumab (Imfinzi) in patients with unresectable (cannot be surgically removed) stage 3 non-small cell lung cancer (NSCLC) who received different combinations of chemoradiotherapy (CRT) previously. The authors found that the use of durvalumab improved survival in all patients previously treated...
Read More
In a nutshell This trial looked at the long-term effectiveness of gefitinib (Iressa) compared to vinorelbine (Navelbine) plus cisplatin (Platinol) for stage II-IIIA EGFR-positive non-small cell lung cancer (NSCLC). The authors found that the use of gefitinib improved disease-free survival (DFS) in these...
Read More
In a nutshell This study compared the use of chemotherapy and bevacizumab (Avastin) or panitumumab (Vectibix) for the treatment of left-sided metastatic colorectal cancer (mCRC) without BRAF/RAS mutations (permanent changes in genes). The study found that both treatment options are effective for these patients. Some background Patients who...
Read More
In a nutshell This study compared 1-year fixed-duration versus continuous nivolumab (Opdivo) for the treatment of previously treated advanced non-small-cell lung cancer (NSCLC). The authors found that continuing nivolumab beyond a fixed duration of 1-year may improve patient outcomes. Some background NSCLC is the most common form of lung cancer....
Read More
